{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:55:50Z","timestamp":1756994150436,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10067-020-04991-y","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T13:02:45Z","timestamp":1582894965000},"page":"2291-2297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California"],"prefix":"10.1007","volume":"39","author":[{"given":"Noopur","family":"Goel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Torralba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8285-5701","authenticated-orcid":false,"given":"Christina","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Salto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"issue":"10","key":"4991_CR1","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1002\/eji.1830211039","volume":"21","author":"C Haworth","year":"1991","unstructured":"Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21(10):2575\u20132579","journal-title":"Eur J Immunol"},{"issue":"5","key":"4991_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"I Solovic","year":"2010","unstructured":"Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Sch\u00f6lvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36(5):1185\u20131206","journal-title":"Eur Respir J"},{"issue":"7","key":"4991_CR3","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1002\/art.21137","volume":"52","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, C\u00f6ster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantap\u00e4\u00e4-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52(7):1986\u20131992","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4991_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10067-016-3462-z","volume":"36","author":"G Cuomo","year":"2017","unstructured":"Cuomo G, D\u2019Abrosca V, Iacono D, Pantano I (2017) The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. Clin Rheumatol 36(2):457\u2013461","journal-title":"Clin Rheumatol"},{"issue":"10","key":"4991_CR5","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1136\/annrheumdis-2014-205376","volume":"74","author":"C Hatzara","year":"2015","unstructured":"Hatzara C et al (2015) Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 74(10):1848\u20131853","journal-title":"Ann Rheum Dis"},{"key":"4991_CR6","unstructured":"Data as reported to World Health Organization. Estimates of TB and MDR TB burden. Generated December 2018"},{"key":"4991_CR7","unstructured":"Tuberculosis Control Branch, Report on Tuberculosis in California, 2017. California Department of Public Health, Richmond, CA. August 2018"},{"issue":"1","key":"4991_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T, American College of Rheumatology (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 68(1):1\u201325","journal-title":"Arthritis Care Res"},{"issue":"6","key":"4991_CR9","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Rodr\u00edguez-Valverde V, Montero D, Pascual-G\u00f3mez E, Mola EM, Carre\u00f1o L, Figueroa M, BIOBADASER Group (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766\u20131772","journal-title":"Arthritis Rheum"},{"key":"4991_CR10","unstructured":"Data from California Department of Public Health, Tuberculosis Control Branch. https:\/\/www.cdph.ca.gov\/Programs\/CID\/DCDC\/Pages\/TB-Disease-Data.aspx. Accessed Jun 2019"},{"issue":"1","key":"4991_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jaad.2018.03.025","volume":"79","author":"J Chung","year":"2018","unstructured":"Chung J, Aronson AB, Srikantha R, Vogelgesang SA, Wanat KA (2018) Low conversion rate of QuantiFERON-TB Gold screening tests in patients treated with tumor necrosis factor inhibitors: a retrospective cohort study identifying an important practice gap. J Am Acad Dermatol 79(1):169\u2013171","journal-title":"J Am Acad Dermatol"},{"key":"4991_CR12","unstructured":"Raza S et al (2016) \u201cConversion rate of tuberculosis screening tests in patients with rheumatic diseases while receiving anti-tumor necrosis factor alpha agents\u201d. American College of Rheumatology Annual Meeting Poster. September 2016"},{"issue":"3","key":"4991_CR13","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, B S R B R Control Centre Consortium, Symmons DP, BSR Biologics Register (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology biologics register (BSRBR). Ann Rheum Dis 69(3):522\u2013528","journal-title":"Ann Rheum Dis"},{"key":"4991_CR14","unstructured":"QuantiFERON-TB Gold ELISA Package Insert"},{"issue":"5","key":"4991_CR15","first-page":"776","volume":"35","author":"D Ponce de Leon","year":"2008","unstructured":"Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C, Medina M, Gamboa R, Ugarte M (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35(5):776\u2013781","journal-title":"J Rheumatol"},{"issue":"4","key":"4991_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1164\/rccm.201209-1621CI","volume":"188","author":"G Redelman-Sidi","year":"2013","unstructured":"Redelman-Sidi G, Sepkowitz KA (2013) IFN-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 188(4):422\u2013431","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"4991_CR17","doi-asserted-by":"publisher","first-page":"e0156917","DOI":"10.1371\/journal.pone.0156917","volume":"11","author":"W Bae","year":"2016","unstructured":"Bae W et al (2016) Comparison of the sensitivity of QuantiFERON-TB Gold in-tube and T-SPOT.TB according to patient age. PLoS One 11(6):e0156917","journal-title":"PLoS One"},{"issue":"2","key":"4991_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1164\/ajrccm.158.2.9709125","volume":"158","author":"K TOCQUE","year":"1998","unstructured":"TOCQUE K et al (1998) Long-term trends in tuberculosis. Am J Respir Crit Care Med 158(2):484\u2013488","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"4991_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1164\/rccm.201203-0430OC","volume":"187","author":"JZ Metcalfe","year":"2013","unstructured":"Metcalfe JZ, Cattamanchi A, McCulloch C, Lew JD, Ha NP, Graviss EA (2013) Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med 187(2):206\u2013211","journal-title":"Am J Respir Crit Care Med"},{"key":"4991_CR20","unstructured":"Schablon A et al (2010) Serial testing with an interferon-\u03b3 release assay in German healthcare workers. GMS Krankenhhyg Interdiszip 5(2)"},{"issue":"4","key":"4991_CR21","doi-asserted-by":"publisher","first-page":"1701267","DOI":"10.1183\/13993003.01267-2017","volume":"50","author":"J Brown","year":"2017","unstructured":"Brown J, Kumar K, Reading J, Harvey J, Murthy S, Capocci S, Hopkins S, Seneviratne S, Cropley I, Lipman M (2017) Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results. Eur Respir J 50(4):1701267","journal-title":"Eur Respir J"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-020-04991-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:42:12Z","timestamp":1614386532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-020-04991-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4991"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-04991-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,2,28]]},"assertion":[{"value":"25 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}